Stoke Therapeutics stockholders elect three Class I directors at 2026 annual meeting

Stoke Therapeutics, Inc.

Elected G. Clare Kahn, Ph.D. (49,722,339 for), Adrian Krainer, Ph.D. (36,531,612 for), and Julie Anne Smith (43,500,649 for) as Class I directors.
Ratified Ernst & Young LLP as independent auditor for FY 2026 with 55,121,163 votes for, 2,036 against.
Advisory vote on named executive officer compensation passed: 36,436,275 for, 13,565,293 against, 29,415 abstaining.

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 1.0

Stoke Therapeutics, Inc. shareholders approved Ratification of the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. at the 2026-06-03 meeting.

Proposal: auditor ratification
Outcome: passed
Meeting: 2026-06-03

Exact text from the filing

Ratification of the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026: Shares For Shares Against Shares Withheld/Abstaining 55,121,163 2,036 51,714

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 1.0

Stoke Therapeutics, Inc. shareholders approved Election of three Class I directors, G. Clare Kahn, Ph.D., Adrian Krainer, Ph.D. and Julie Anne Smith, each to serve a three-year term. at the 2026-06-03 meeting.

Proposal: director election
Outcome: passed
Meeting: 2026-06-03

Exact text from the filing

Election of three Class I directors, G. Clare Kahn, Ph.D., Adrian Krainer, Ph.D. and Julie Anne Smith, each to serve a three-year term, which will expire upon the earlier of the 2029 annual meeting of stockholders or until such time as their respective successors have been duly elected and qualified or their earlier resignation or removal: Nominees Shares For Shares Withheld Broker Non-Votes G. Clare Kahn, Ph.D. 49,722,339 308,644 5,143,930 Adrian Krainer, Ph.D. 36,531,612 13,499,371 5,143,930 Julie Anne Smith 43,500,649 6,530,334 5,143,930

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 1.0

Stoke Therapeutics, Inc. shareholders approved Approval, on a non-binding advisory basis, of the compensation of the Company’s named executive officers as disclosed in the Company’s definitive proxy statement filed with the U.S. Securities and Exchange Commission on April 22, 2026. at the 2026-06-03 meeting.

Proposal: say on pay
Outcome: passed
Meeting: 2026-06-03

Exact text from the filing

Approval, on a non-binding advisory basis, of the compensation of the Company’s named executive officers as disclosed in the Company’s definitive proxy statement filed with the U.S. Securities and Exchange Commission on April 22, 2026: Shares For Shares Against Shares Withheld/Abstaining Broker Non-Votes 36,436,275 13,565,293 29,415 5,143,930

View on SEC.gov

303 shareholder votes filed in the last 30 days. Browse all shareholder votes →

Stoke Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-257394

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.